Caseous D-T (Canada)This page contains information on Caseous D-T for veterinary use.
The information provided typically includes the following:
- Caseous D-T Indications
- Warnings and cautions for Caseous D-T
- Direction and dosage information for Caseous D-T
Caseous D-TThis treatment applies to the following species:
CLOSTRIDIUM TETANI-PERFRINGENS TYPE D-CORYNEBACTERIUM PSEUDOTUBERCULOSIS BACTERIN-TOXOID
This product is a combination of three antigenic substances adequate, when administered to healthy sheep according to label directions, to protect against (1) enterotoxemia caused by Clostridium perfringens, Type D, (2) toxemia caused by Clostridium tetani, and (3) to aid in the prevention and control of Caseous lymphadenitis, a disease characterized by localized collections of pus in the tissues of the body caused by Corynebacterium pseudotuberculosis. These suppurative inflammations are most often referred to as abscesses but at times, when the disease is being discussed by those familiar with it, are also called boils.
Caseous lymphadenitis is a chronic disease of sheep, goats, and other small ruminants in which clinical signs and lesions may not be observed for several months after the animals become infected. Causative bacteria are likely to be present on the skin of susceptible animals and exposure may occur through wounds resulting from shearing, scratches, splinters, thorns, and the like. Abrasions provide access to the organism which thereafter migrates to the lymph nodes of the body. Exposure may also occur by pulmonary transfer so over-crowding of animals should also be avoided. The disease is not usually fatal but condemnations may run as high as 20% when carcasses are inspected following slaughter. Weakness and emaciation may develop in animals that are not held for slaughter, followed by eventual death.
The disease is manifested in two forms: (1) external abscesses in the superficial (mandibular, prescapular, and prefemoral) lymph nodes and (2) internal abscesses in the visceral organs especially in the lung, liver, and kidney and in the mediastinal, bronchial, and lumbar lymph nodes. Both forms may occur simultaneously. The visceral form of the disease is implicated in the “thin ewe syndrome” and can cause loss of fertility.
Abscesses and lesions formed in Caseous lymphadenitis have a cheesy greenish-yellow to off-white odorless pus surrounded by a capsule. These lesions progressively enlarge. In older abscesses the pus becomes somewhat dry and firm and will form concentric layers within the fibrous capsule. C. pseudotuberculosis is easily isolated from such abscesses and usually is the only organism present.
Once the disease has been introduced into a flock of sheep a relatively large percentage of susceptible animals will be affected. The organism is likely to spread by contamination from ruptured or lanced abscesses or at shearing time. Any infected animals should be shorn last and the shearing equipment thereafter sterilized. It is essential, in the control of Caseous lymphadenitis, to exercise strict herd management with careful attention to examination, treatment, separation, and culling of infected animals.
It has been shown that this product will control Caseous lymphadenitis when sheep are vaccinated prior to exposure to the disease. It has also been shown that little or no benefit can be expected when animals with visible signs of the disease are vaccinated. Those showing infection should be immediately culled from the flock and disposed of or held away from those animals that appear to be in good health.
Enterotoxemia is most common in younger sheep and goats being fed a high carbohydrate diet which is a general practice in most feedlots. Animals on grass may also become infected but less frequently. Clostridium tetani is found in the intestinal tracts of most animals. It is introduced into tissues in much the same manner as the micro-organism that causes Caseous lymphadenitis. This single product is adequate for all three diseases.
Do not vaccinate within 21 days before slaughter.
Anaphylactoid reaction may occur following administration of products of this nature. If noted, administer adrenalin or equivalent. Handling of the product, filling of syringes, etc., should be done as aseptically as possible. Great care has been taken to assure the purity of this preparation at the time of release for marketing. Reasonable precautions should be taken in the field to maintain this condition.
Slight lameness (soreness) in lambs and lethargy in mature sheep may be observed in a percentage of the animals following vaccination. Sheep are inclined to become depressed or will limp when foreign substances are administered or because of the increased exertion and stimulation of vaccination. While noticeable, these symptoms usually disappear within 24-48 hours and can be considered as minor vaccination reactions. If suggested care is taken in preparing vaccination equipment and in administering the product there should no abscessation at the site of injection.
Caseous D-T Dosage And Administration
Inject 2 ml subcutaneously (axillary space). Repeat the full 2 ml dose 4 weeks later (axillary space opposite to the first dose). A “booster” dose of 2 ml should be administered annually.
1. Shake well before use.
2. Use entire contents when first opened.
3. Store at 2° to 7° C. Do not freeze.
4. Contains thimerosal as a preservative.
5. Sterilize needles and syringes by boiling in clean water.
6. Conveniently packaged in 10 dose and 50 dose bottles.
USDA Code 7894.00
U.S. Vet. License No. 188
Manufactured by: COLORADO SERUM COMPANY, 4950 York Street, Denver, Colorado 80216
Contact us for more information on other Colorado Serum Company products.
Fine Veterinary Biologics since 1923
FOR VETERINARY USE ONLY
Distributed in Canada by: BIONICHE ANIMAL HEALTH CANADA INC.
NAC No.: 11740052
4950 YORK STREET, P.O. BOX 16428-0428, DENVER, CO, 80216-0428
|Every effort has been made to ensure the accuracy of the Caseous D-T information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2014 North American Compendiums. Updated: 2014-05-28